Tag: oncology

Posted on March 26, 2018

Computational Analysis And Intelligent Computing Systems To Assist Oncologists With Personalized Cancer Treatments:

RCM Provides Advanced Computational Analysis to Assist Oncologists in Delivering Personalized Cancer Treatments based on Genetic Markers   The research is clear:  Genetic markers of cancer, which are identified through an analysis of cancer DNA in a lab, can help oncologists personalize treatments for improved outcomes and prolonged survival rates.   Here’s how it works:  Oncologist receive […]

Posted on January 6, 2017

GETTING MOLECULAR PROFILING TESTING DONE FOR CANCER: Raymond Rupert MD, MBA.

Personalized and targeted treatments for cancer are based on the molecular profiling of the cancer’s DNA. Each patient’s cancer can be unique. Once the driver mutations in the cancer’s DNA are recognized by the lab tests, then specific cancer drugs can be prescribed.  These are known as actionable treatment strategies. These new cancer drugs are […]

Posted on November 18, 2016

Overall Survival in Many Cancer Drug Trials Provides Marginal Versus Real Improvements:

Sham Mailankody, MB, BS1; Vinay Prasad, MD, MPH2,3 Author Affiliations JAMA Oncol. Published online November 17, 2016. doi:10.1001/jamaoncol.2016.5296 Cancer regulatory approvals aim to permit drugs to be marketed to improve survival or quality of life for patients. Approximately one-third of cancer drugs approved come to market on the basis of demonstrated improvement in overall survival in randomized clinical trials, […]

Posted on December 1, 2015

NEW BLOOD TEST FOR CANCER IDENTIFIES THE PRESENCE AND ORIGIN OF THE TUMOUR:

Dr. D. James Morré, PhD – Co-Founder and Director of Research: Discovery of the ENOX2 Serum Cancer Marker The ENOX proteins comprise a family of cell surface enzymes that are essential to the growth phase of cell proliferation. One member of this family, ENOX2, is universally produced by cancer cells after malignant transformation due to […]

Posted on October 6, 2015

Economic value of the utility-expansion for new cancer drugs approved in Canada from 2004 to 2014.

Summary Authors: Kimberley Tran (M.A.); Brett J Skinner (Ph.D.) In the Canadian health technology assessment (HTA) process, drugs are evaluated for clinical and cost-effectiveness following Health Canada marketing approval. Usually, each drug indication is evaluated by HTA bodies individually in line with the specific indication granted by Health Canada. However, when a cancer drug is […]